Die Suchmaschine für Unternehmensdaten in Europa
EU-Förderung (9.526.097 €): Verankerte Muskel-CELls für IncontinencE Hor 15.05.2020 EU-Rahmenprogramm für Forschung und Innovation "Horizont"
Auf einen Blick
Text
Verankerte Muskel-CELls für IncontinencE
Faecal incontinence (FI) is a common condition affecting ~67 million people in Europe, seriously impairing living and productivity of affected individuals and their families. Women with FI arising from childbirth injury may benefit from regenerative medicine using autologous skeletal muscle derived cells (ASMDC) to restore function of damaged sphincter muscle. However, progress is hindered by sub-optimal manufacturing and delivery techniques contributing to inconsistent results. AMELIE proposes an innovative approach that uses ASMDC attached to implantable microcarriers that will enable delivery of a higher number of viable ASMDC into the damaged sphincter muscle, increasing the likelihood of cell engraftment, regeneration of muscle and improved continence. To achieve this, AMELIE will develop bespoke implantable microcarriers suitable for clinical use; establish robust bioprocessing for manufacture of the cell-microcarrier combination; and for the first time, robustly test, in a clinical study, the principle that delivery of ASMDC in an anchored, natural state, are safe and provide more effective and consistent treatment. AMELIE comprises a highly interdisciplinary, gender balanced, consortium of internationally recognised experts and key-opinion leaders with relevant experience from academia and industry across Europe in the fields of engineering (IST, UCL, NHSBT), biological sciences (NHSBT, UCL, IISFJD), and translational regenerative medicine (QMUL, MUG, AUH, AU, RUH, UHE, IISFJD, CVBF). BCR will lead dissemination activity and stakeholder interaction with patients and the public, healthcare professionals, industry and third party FI charities across Europe to establish reciprocal dialogue with people that will interact with the new technology throughout the lifetime of the AMELIE project. PNO LSH will lead knowledge management and exploitation to develop a marketing strategy and business plan to facilitate future exploitation of the technology to ensure patient benefit.
Geförderte Unternehmen:
| Firmenname | Förderungssumme |
| Aarhus Universitet | 17.432,98 € |
| Aarhus Universitetshospital | 84.397 € |
| Bowel & Cancer Research | 337.382 € |
| Centre Hospitalier Rouen | 46.007 € |
| Consorzio Per Valutazioni Biologiche E Farmacologiche | 797.887 € |
| Instituto Investigacion Sanitaria Fundacion Jimenez Diaz | 224.300 € |
| Instituto Superior Tecnico | 459.913 € |
| Medizinische Universitat Graz | 74.270 € |
| NHS Blood and Transplant | 1.797.375 € |
| PNO Life Sciences & Health B.V. | 180.750 € |
| Queen Mary University of London | 1.141.603 € |
| Universitatsklinikum Erlangen | 74.641 € |
| University College London | 4.290.140 € |
Quelle: https://cordis.europa.eu/project/id/874807
Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider.